

# Varespladib

**Catalog No: tcsc1018**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

172732-68-2

**Formula:**

$C_{21}H_{20}N_2O_5$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

Phospholipase

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O :

**Alternative Names:**

LY315920

**Observed Molecular Weight:**

380.39

## Product Description


LY315920 (Varespladib) is a potent and selective human non-pancreatic secretory phospholipase A2 (sPLA2) inhibitor with IC<sub>50</sub> of 7 nM.

IC<sub>50</sub> value: 7 nM

Target: sPLA2

in vitro: LY315920 exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC<sub>50</sub> of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively. [2] In BAL cells challenged with human sPLA2, LY315920 at doses ranging from 0.1  $\mu$ M–3  $\mu$ M reduces the formation of thromboxane mediated by human sPLA2 in a concentration-dependent manner with an IC<sub>50</sub> of approximately 0.8  $\mu$ M. [2] In human conjunctival epithelial cell line (HCjE), LY315920 (10  $\mu$ M) significantly inhibits all-trans-retinoic acid (RA) -induced membrane-associated mucin MUC16 expression by 100% at 24 hours and 99% at 48 hours. [3]

in vivo: Ex vivo, LY315920 at doses ranging from 3 mg/kg to 30 mg/kg via i.v. inhibits human sPLA2-induced release of thromboxane from guinea pig BAL cells with ED<sub>50</sub> of 16.1 mg/kg. [2] In Transgenic Mice Expressing Human sPLA2, both oral and i.v. administration of LY315920 (0.3 mg/kg–3 mg/kg) abolishes serum sPLA2 activity in a dose and time dependent manner. [2]



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!